First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018
IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus atezolizumab) combination in first-line metastatic triple negative breast cancer (TNBC) patients.
IMpower130 demonstrated significant overall survival (OS) and progression-free survival (PFS) benefit of ABRAXANE/carboplatin plus atezolizumab in advanced non-squamous non-small cell lung cancer (NSCLC) patients.
These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than the U.S., please contact the local office (as listed under the Global Network).